Silexion's SIL204 showed strong anti-tumor effects in preclinical tests, reaching major metastasis sites in pancreatic cancer models at human-relevant doses.

Investing.com -- Silexion Therapeutics Corp. (NASDAQ:SLXN) stock soared 400% after the company reported positive preclinical data for its pancreatic cancer drug SIL204, demonstrating the treatment’s ...

Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid ...

Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.

Silexion Therapeutics Corp. (NASDAQ:SLXN) saw its stock surge 400% after unveiling positive preclinical findings for its ...

Discover Alector's latest breakthroughs in neurodegenerative disease therapies, including updates on Alzheimer's and Parkinson's programs.

Silexion Therapeutics (SLXN) announced new preclinical data demonstrating that subcutaneously administered SIL204 successfully reaches all primary sites of pancreatic cancer metastasis and shows ...

Leqembi Iqlik's subcutaneous injection for Alzheimer's disease received FDA approval, based on Phase III trial data showing comparable efficacy to IV dosing. The subcutaneous formulation demonstrated ...

Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...